Evidence map›Paper›PMID 22649252›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2012

Toll/interleukin-1 receptor domain-containing adapter inducing interferon-β mediates microglial phagocytosis of degenerating axons.

Suneil Hosmane, Million Adane Tegenge, Labchan Rajbhandari, Prech Uapinyoying, Nishant Ganesh Kumar, Nitish Thakor, Arun Venkatesan

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 96 citations in OpenAlex.

  1. Review
  2. Research Progress on Neural Cell Culture Systems.Current neuropharmacology · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. The Contribution of Microglia to Neuroinflammation in Parkinson's Disease.International journal of molecular sciences · 2021
    Review
  12. Review
  13. Sensors international · 2021
    Article
  14. Human mini-brain models.Nature biomedical engineering · 2021
    Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Suneil HosmaneDepartments of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Million Adane Tegenge
Labchan Rajbhandari
Prech Uapinyoying
Nishant Ganesh Kumar
Nitish Thakor
Arun Venkatesan
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

Impairment of Adult Hippocampal Neurogenesis by Methamphetamines and HIVK08DA022946 · NIDA · JOHNS HOPKINS UNIVERSITY · PI VENKATESAN, ARUN · 2007 to 2011
$923k
Innovative Technologies to Study Mechanisms of CNS Axonal DegenerationF31NS066753 · NINDS · JOHNS HOPKINS UNIVERSITY · PI HOSMANE, SUNEIL · 2009 to 2011
$105k
Howard Hughes Medical InstituteNIDA NIH HHS K08 DA022946NIDA NIH HHS K08DA22946NINDS NIH HHS 1F31NS066753-01NINDS NIH HHS F31 NS066753
6 · The paper itself

Abstract

Following CNS injury, microglial phagocytosis of damaged endogenous tissue is thought to play an important role in recovery and regeneration. Previous work has focused on delineating mechanisms of clearance of neurons and myelin. Little, however, is known of the mechanisms underlying phagocytosis of axon debris. We have developed a novel microfluidic platform that enables coculture of microglia with bundles of CNS axons to investigate mechanisms of microglial phagocytosis of axons. Using this platform, we find that axon degeneration results in the induction of type-1 interferon genes within microglia. Pharmacologic and genetic disruption of Toll/interleukin-1 receptor domain-containing adapter inducing interferon-β (TRIF), a Toll-like receptor adapter protein, blocks induction of the interferon response and inhibits microglial phagocytosis of axon debris in vitro. In vivo, microglial phagocytosis of axons following dorsal root axotomy is impaired in mice in which TRIF has been genetically deleted. Furthermore, we identify the p38 mitogen-activated protein kinase (MAPK) cascade as a signaling pathway downstream of TRIF following axon degeneration and find that inhibition of p38 MAPK by SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole) also blocked clearance of axon debris. Finally, we find that TRIF-dependent microglial clearance of unmyelinated axon debris facilitates axon outgrowth. Overall, we provide evidence that TRIF-mediated signaling plays an unexpected role in axonal debris clearance by microglia, thereby facilitating a more permissive environment for axonal outgrowth. Our study has significant implications for the development of novel regenerative and restorative strategies for the many traumatic, neuroinflammatory, and neurodegenerative conditions characterized by CNS axon degeneration.

Indexed as

Adaptor Proteins, Vesicular TransportAdenosine TriphosphateAnalysis of VarianceAnimalsAnimals, NewbornAxonsAxotomyCD11b AntigenCells, CulturedChemokine CXCL10Coculture TechniquesDisease Models, AnimalEmbryo, MammalianEnzyme InhibitorsGanglia, SpinalGene Expression RegulationAdaptor Proteins, Vesicular TransportAdenosine TriphosphateCD11b AntigenChemokine CXCL10Cxcl10 protein, mousediethylammonium-1-(N,N-diethylamino)diazen-1-ium-1,2-diolateEnzyme InhibitorsImidazolesInterferon-betaNitric OxidePeptidesPyridinesQuaternary Ammonium CompoundsReceptors, Interleukin-1SB 203580Ticam1 protein, mouse

Identifiers

PMID22649252
PMCPMC3398425
OpenAlexW2031170591

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.